2021 USPSTF Lung Cancer Screening Criteria Expand Eligibility
Among patients with lung cancer, 65% were eligible for screening with 2021 USPSTF criteria and 49% were eligible with 2013 USPSTF criteria.
Lung Cancer
Elevated Platelet Count Could Be a Biomarker for Several Cancers
Compared with patients who had a medium platelet count, patients with a very high platelet count had more than double the risk of a solid tumor diagnosis.
Radiotherapy Did Not Improve Upon Immunotherapy in Metastatic NSCLC
Radiotherapy did not improve response rates or survival outcomes.
Method Improves Risk Assessment for Lung Cancer Screening
The approach improved risk assessment compared with 2021 USPSTF screening criteria.
Incidence of Advanced Lung Cancer Continues to Decline in the U.S.
Researchers projected that 1,918,030 new cancer cases and 609,360 cancer deaths will occur in the United States in 2022, including about 350 deaths per day from lung cancer.
Giving Immune Checkpoint Inhibitors Within 90 Days of Radiation Appears Safe
Rates of adverse events were generally similar between patients who did and did not receive radiation.
Camrelizumab Improves PFS, OS in Non-Small Cell Lung Cancer
Adding camrelizumab to chemotherapy reduced the risk of death by 45%.
Stage Shift Tied to Decreased Population Mortality in NSCLC
A diagnostic shift from later-stage to earlier-stage disease may have implications for the evaluation of treatments and mortality outcomes.
COVID-19 and Lung Cancer: What We Know and Don’t Know
Researchers have summarized what is known about COVID-19 in the context of lung cancer and highlighted areas where more research is needed.
Extending Dosing Interval May Not Impact Safety, Efficacy of ICIs in Lung Cancer
Survival outcomes were similar for patients with an extended dosing interval and patients who received standard dosing.
- Loading...
Loading...
Next post in Lung Cancer
Loading... 
Loading...